Colgate-Palmolive Company (CL) 2024 10-K Earnings Analysis
Colgate-Palmolive Company2024 Earnings Analysis
81/100
Colgate-Palmolive Company's 10-K for the period ended December 31, 2024 shows a company with real operating weight: $20.1B of revenue, $2.89B of net income, and $3.55B of free cash flow. Hill's Pet Nutrition, Emerging-Markets Footprint, and Volume vs Pricing remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. Margins held at 60.5% gross and 21.2% operating, and that is easier to believe once you look at Hill's Pet Nutrition. The open question is not whether these risks exist but whether volume vs Pricing, emerging-Markets FX, and private-Label Competition can all be handled without breaking the economics.
Filing analysis
Colgate-Palmolive Company 2024 10-K Analysis
This page reads Colgate-Palmolive Company's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 81/100, or grade B.
CL Earnings Quality
The earnings-quality module scores 83/100, with Gross Margin: 60.5%, Operating Margin: 21.2%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
CL Economic Moat Analysis
The moat-strength module scores 85/100, with Oral Care Leadership: Toothpaste category leader, Hill's Pet Nutrition: Premium pet food. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
CL Free Cash Flow vs Net Income
CF/Net Income: 1.42x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 80/100. For the diagnostic, start with cash flow vs net income.
CL Key Risks from the Annual Report
The risk module scores 75/100, with Volume vs Pricing: Pricing-led growth, Emerging-Markets FX: Currency translation. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is CL a High Quality Earnings Stock?
Based on this 2024 filing, CL passes the first screen for high-quality earnings: the overall grade is B, and the earnings-quality score is 83/100. This is a research screen, not investment advice.
Read the report first
Understand Colgate-Palmolive Company first, then decide if it belongs on your watchlist
The CL score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep CL with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the CL report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
The significance of gross margin in FY2024 is that the significance of gross margin in FY2024 is that gross margin of 60.5% reflects the disclosed branded personal care product mix.
Operating Margin is worth reading alongside the rest of the file because operating Margin is worth reading alongside the rest of the file because the 21.2% operating margin reflects the disclosed pricing-realization plus revenue growth management execution per the segment-disclosure communications.
On cf / net income, the useful point is that on cf / net income, the useful point is that OCF of $4.11B is 1.42x net income of $2.89B — reflecting depreciation per the cash-flow reconciliation.
The reason FY2024 looks credible is that the accounting result and the cash result are moving together: $2.89B of net income came with $4.11B of operating cash flow and $3.55B of free cash flow. Hill's Pet Nutrition and Emerging-Markets Footprint give the filing a business explanation for why cash conversion stayed solid. The filing therefore looks like an operating story first and a financing story second: Hill's Pet Nutrition supports 21.2% operating margin, then cash conversion, then capital returns. Because Hill's Pet Nutrition is still producing strong cash conversion, the reported earnings line looks grounded rather than cosmetic.
Moat Strength
Oral Care Leadership is useful mainly because oral Care Leadership is useful mainly because colgate is the global toothpaste-category leader per public Nielsen-share data — a multi-decade competitive position as described in the market-share communications.
Hill's Pet Nutrition matters because hill's Pet Nutrition matters because hill's Pet Nutrition (Science Diet + Prescription Diet as described in the brand-line) holds a leading premium pet food position per public industry-data.
What emerging-markets footprint really tells you is that what emerging-markets footprint really tells you is that and Africa per the regional-segment list.
If you want the moat in plain language, start with Hill's Pet Nutrition and Emerging-Markets Footprint. Volume vs Pricing and Emerging-Markets FX help explain why the company can defend pricing or wallet share without needing a monopoly narrative. What matters is that Hill's Pet Nutrition still delivered 1362.7% ROE without sacrificing the cash profile or the operating position. That is the practical moat test: a competitor has to dislodge Hill's Pet Nutrition-driven behavior, not just underprice a SKU.
Capital Allocation
The allocation takeaway from free cash flow is that the allocation takeaway from free cash flow is that FCF of $3.55B (OCF $4.11B minus capex $561M) supports the disclosed dividend and share-repurchase program.
Dividend Growth is relevant because dividend Growth is relevant because colgate has paid uninterrupted dividends since 1895 and has increased dividends for 60+ consecutive years as described in the dividend-aristocrat communications.
On negligible equity, the file suggests that on negligible equity, the file suggests that stockholders' equity of $212M reflects substantial cumulative share repurchases per the equity-statement disclosures.
The reason capital allocation matters here is simple: after paying to maintain Hill's Pet Nutrition and the rest of the platform, the business still threw off $3.55B of free cash flow. Capex is modest at 2.8% of revenue, so the real decision is how management redeploys the cash left over. Liquidity is workable at $1.10B, but the debt stack at $7.00B keeps the company tied to continued cash generation. Per the FY2024 annual report and company disclosures, the payout framework uses both dividends and repurchases, which works only while cash generation remains solid.
Key Risks
The risk significance of volume vs pricing is that the risk significance of volume vs pricing is that recent organic-revenue growth has been principally pricing-led as described in the volume mix pricing decomposition — volume contribution has been modest.
Emerging-Markets FX belongs on the watch list because emerging-Markets FX belongs on the watch list because the approximately 50% emerging-markets revenue mix creates FX-translation exposure as described in the regional-currency breakdown.
The point of private-label competition is that the point of private-label competition is that private-label and consumer trade down dynamics per public industry data affect category-share trajectory in some regions.
The filing makes the risk picture look cumulative: Volume vs Pricing, Emerging-Markets FX, and Private-Label Competition can each hurt the others. The risk file matters because Volume vs Pricing and Emerging-Markets FX can still compound into a weaker cash outcome. Acquisition discipline remains relevant with goodwill at 20.4% of assets, especially where Hill's Pet Nutrition still needs follow-through. The open question is not whether these risks exist but whether volume vs Pricing, emerging-Markets FX, and private-Label Competition can all be handled without breaking the economics.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.